Brii Biosciences

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Retrieved on: 
Wednesday, April 21, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Medical specialties, Clinical medicine, Infectious diseases, Hepadnaviridae, Hepatitis B, Hepatitis, HBV, BRII-835 (VIR-2218), BRII-179 (VBI-2601), Brii Biosciences, Vir Biotechnology, VBI Vaccines Inc., BRII-835 (VIR-2218), BRII-179 (VBI-2601), BRII BIOSCIENCES, VIR BIOTECHNOLOGY, VBI VACCINES INC.

This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.

Key Points: 
  • This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.\nThis press release features multimedia.
  • Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
  • Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Retrieved on: 
Wednesday, April 21, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Hepadnaviridae, HBV, Hepatitis B, Infectious diseases, Clinical medicine, BRII-835 (VIR-2218), BRII-179 (VBI-2601), Brii Biosciences, Vir Biotechnology, VBI Vaccines Inc., BRII-835 (VIR-2218), BRII-179 (VBI-2601), BRII BIOSCIENCES, VIR BIOTECHNOLOGY, VBI VACCINES INC.

Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).

Key Points: 
  • Both agents have demonstrated proof of mechanism in HBV patients ( NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study).
  • Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV.
  • VIR-2218 is the first asset in the Company\xe2\x80\x99s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
  • Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus.

Brii Biosciences Closes US$155 Million Series C Financing

Retrieved on: 
Tuesday, March 23, 2021
Venture capital, Biotechnology, Pharmaceutical, Finance, Health, Infectious diseases, Professional services, Clinical trials, Medical terminology, Actuarial science, Disease, Brii Biosciences, Invesco Developing Markets Fund, GIC, Lake Bleu Capital

Brii Biosciences (Brii Bio), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced completion of a Series C financing of US$155 million.

Key Points: 
  • Brii Biosciences (Brii Bio), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burden, today announced completion of a Series C financing of US$155 million.
  • Proceeds from the financing will be used to advance Brii Bios broad infectious diseases pipeline as well as the companys CNS program.
  • Brii Bio is currently conducting clinical studies in multiple infectious diseases, and is preparing to enter clinical-stage research in diseases of the central nervous system.
  • Brii Bio is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and CNS diseases.

VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection

Retrieved on: 
Wednesday, November 18, 2020
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Medicine, Virology, Hepadnaviridae, Hepatitis B, Vaccine, Hepatitis, Hepatitis B, VBI Vaccines Inc., Brii Biosciences

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical results from the ongoing Phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection, in development in collaboration with Brii Biosciences.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced positive interim clinical results from the ongoing Phase 1b/2a study of VBI-2601 (BRII-179), a novel recombinant, protein-based immunotherapeutic candidate for the treatment of chronic hepatitis B virus (HBV) infection, in development in collaboration with Brii Biosciences.
  • This study was designed to assess the ability of VBI-2601 (BRII-179) to induce or restore antibody and T cell responses against HBV.
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.